TECOGEN INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TECOGEN INC. on December 5, 2013. The report details a private placement transaction involving the sale of common stock to accredited investors.
Key Financial Metrics
- Capital Raised: $90,000 aggregate purchase price.
- Shares Issued: 20,000 shares of common stock ($0.001 par value).
- Price Per Share: $4.50.
- Transaction Fees: $6,075 (6.75% of gross proceeds) paid to investment banks.
- Use of Proceeds: General corporate and working capital purposes.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this report focuses solely on the equity transaction.
Material Changes
The primary material change is the increase in outstanding common stock by 20,000 shares and the receipt of $90,000 in cash proceeds. The Company is required to file a registration statement covering the resale of these shares by the investors.
Outlook, Risks, and Unusual Items
The sale was conducted as a private placement without registration under the Securities Act of 1933, relying on exemptions under Section 4(a)(2) and Regulation D. The shares are restricted and may not be re-offered or sold in the United States absent an effective registration statement or applicable exemption. No specific guidance or management commentary regarding future operations was included in this filing.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the filing of the required registration statement for the resale of the 20,000 shares.
- Review the full text of the Common Stock Purchase Agreement (Exhibit 10.1 referenced from the November 13, 2013 filing) for additional covenants.
- Assess the company's current cash position to determine the significance of the $90,000 infusion relative to working capital needs.